{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:44:32Z","timestamp":1764791072746,"version":"3.46.0"},"reference-count":44,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12,1]]},"abstract":"<jats:p>A 4-factor prothrombin complex concentrate (4F-PCC), containing therapeutic doses of vitamin K\u2013dependent coagulation factors, was recently licensed in the United States for reversal of vitamin K antagonist therapy. However, given the emergence of several oral anticoagulants for which there are no specific reversal agents, and the existence of many other complex bleeding disorders, it is likely that clinicians will seek to use 4F-PCCs for any number of off-label indications. Thus, the goal of this review is to explore practical issues regarding 4F-PCC, with an emphasis on issues relevant to blood bankers and pathologists. Specifically, our aims are to (1) examine the role of 4F-PCC in vitamin K antagonist reversal, (2) review its potential use in the treatment of hemorrhage due to novel oral anticoagulants, and (3) explore potential uses in liver disease, trauma-associated bleeding, and rare coagulopathies. Safety and other practical considerations of 4F-PCCs will also be discussed.<\/jats:p>","DOI":"10.5858\/arpa.2014-0366-rs","type":"journal-article","created":{"date-parts":[[2015,11,30]],"date-time":"2015-11-30T18:32:10Z","timestamp":1448908330000},"page":"1568-1575","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Applications of 4-Factor Prothrombin Complex Concentrate: A Practical Pathologist's Perspective"],"prefix":"10.5858","volume":"139","author":[{"given":"David","family":"Unold","sequence":"first","affiliation":[{"name":"From the Department of Laboratory Medicine, Yale University School of Medicine, New Haven, Connecticut (Drs Unold and Tormey); BloodSource, Inc, Mather, California (Dr Unold); and Pathology & Laboratory Medicine Service, VA Connecticut Healthcare System, West Haven, Connecticut (Dr Tormey)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Tormey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"key":"2020081220210660800_i1543-2165-139-12-1568-b01","unstructured":"CSL Behring full prescribing Information: Kcentra prothrombin complex concentrate (human)\n          [electronic prescribing information]. CSL Behring. http:\/\/labeling.cslbehring.com\/PI\/US\/Kcentra\/EN\/Kcentra-Prescribing-Information.pdf. AccessedJune142014."},{"issue":"2 suppl","key":"2020081220210660800_i1543-2165-139-12-1568-b02","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"5","key":"2020081220210660800_i1543-2165-139-12-1568-b03","first-page":"217","article-title":"Diagnosis, treatment, and reporting of adverse effects of transfusion","volume":"43","author":"Torres","year":"2012","journal-title":"LabMedicine"},{"issue":"3","key":"2020081220210660800_i1543-2165-139-12-1568-b04","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3171\/2011.11.JNS11836","article-title":"Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage","volume":"116","author":"Sarode","year":"2012","journal-title":"J Neurosurg"},{"issue":"8","key":"2020081220210660800_i1543-2165-139-12-1568-b05","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.ajem.2013.05.008","article-title":"Experiences with an activated 4-factor prothrombin complex concentrate (FEIBA) for reversal of warfarin-related bleeding","volume":"31","author":"Stewart","year":"2013","journal-title":"Am J Emerg Med"},{"key":"2020081220210660800_i1543-2165-139-12-1568-b06","unstructured":"FEIBA NF (anti-inhibitor coagulant complex), nanofiltered and vapor heated\n          [electronic prescribing information]. Baxter Healthcare Corporation. http:\/\/www.baxter.com\/downloads\/healthcare_professionals\/products\/feiba-nf-pi.pdf. Revised February 2011. AccessedJune142014."},{"issue":"10","key":"2020081220210660800_i1543-2165-139-12-1568-b07","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/j.1742-1241.2008.01859.x","article-title":"Biochemical comparison of seven commercially available prothrombin complex concentrates","volume":"62","author":"Kalina","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"4","key":"2020081220210660800_i1543-2165-139-12-1568-b08","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1160\/TH07-05-0367","article-title":"Pharmacokinetics of Beriplex P\/N prothrombin complex concentrate in healthy volunteers","volume":"98","author":"Ostermann","year":"2007","journal-title":"Thromb Haemost"},{"issue":"11","key":"2020081220210660800_i1543-2165-139-12-1568-b09","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"issue":"6027","key":"2020081220210660800_i1543-2165-139-12-1568-b10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.2.6027.83","article-title":"Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal","volume":"2","author":"Taberner","year":"1976","journal-title":"Br Med J"},{"issue":"8","key":"2020081220210660800_i1543-2165-139-12-1568-b11","first-page":"1","article-title":"The role of prothrombin complex concentrates in reversal of target specific anticoagulants","volume":"12","author":"Babilonia","year":"2014","journal-title":"Thromb J"},{"issue":"4","key":"2020081220210660800_i1543-2165-139-12-1568-b12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"issue":"18","key":"2020081220210660800_i1543-2165-139-12-1568-b13","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for Dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2020081220210660800_i1543-2165-139-12-1568-b14","doi-asserted-by":"crossref","first-page":"E1825","DOI":"10.1016\/S0735-1097(13)61825-2","article-title":"Evaluation of a specific antidote to Dabigatran: in vitro properties, pharmacokinetics and reversal of Dabigatran etexilate-induced bleeding in rats [abstract]","volume":"61","author":"Van Ryn","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2020081220210660800_i1543-2165-139-12-1568-b15","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2215\/CJN.01570213","article-title":"Extracorporeal therapy for Dabigatran removal in the treatment of acute bleeding: a single center experience","volume":"8","author":"Singh","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"2020081220210660800_i1543-2165-139-12-1568-b16","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1538-7836.2012.04859.x","article-title":"Reversal of Dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P\/N) in a rabbit model","volume":"10","author":"Pragst","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2020081220210660800_i1543-2165-139-12-1568-b17","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011","journal-title":"Stroke"},{"issue":"6","key":"2020081220210660800_i1543-2165-139-12-1568-b18","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1097\/ALN.0000000000000255","article-title":"Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation","volume":"120","author":"van Ryn","year":"2014","journal-title":"Anesthesiology"},{"issue":"9","key":"2020081220210660800_i1543-2165-139-12-1568-b19","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/j.1538-7836.2012.04863.x","article-title":"Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate","volume":"10","author":"Lambourne","year":"2012","journal-title":"J Thromb Haemost"},{"key":"2020081220210660800_i1543-2165-139-12-1568-b20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1160\/TH12-12-0907","article-title":"Reversal of Rivaroxaban anticoagulation by haemostatic agents in rats and primates","volume":"110","author":"Perzborn","year":"2013","journal-title":"Thromb Haemost"},{"issue":"1","key":"2020081220210660800_i1543-2165-139-12-1568-b21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/ALN.0b013e318238c036","article-title":"Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse Rivaroxaban in a rabbit model","volume":"116","author":"Godier","year":"2012","journal-title":"Anesthesiology"},{"issue":"14","key":"2020081220210660800_i1543-2165-139-12-1568-b22","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"2020081220210660800_i1543-2165-139-12-1568-b23","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12599","article-title":"Comparison of three- and four-factor prothrombin complex concentrates on the anticoagulant effects of rivaroxaban in healthy volunteers","author":"Levi","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2020081220210660800_i1543-2165-139-12-1568-b24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00042737-200301000-00004","article-title":"Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage","volume":"15","author":"Lorenz","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"2020081220210660800_i1543-2165-139-12-1568-b25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MBC.0b013e328351250f","article-title":"Prothrombin complex concentrate (Octaplex): a Portuguese experience in 1152 patients","volume":"23","author":"Carvalho","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2020081220210660800_i1543-2165-139-12-1568-b26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2482-13-22","article-title":"Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial","volume":"13","author":"Arshad","year":"2013","journal-title":"BMC Surg"},{"issue":"4","key":"2020081220210660800_i1543-2165-139-12-1568-b27","first-page":"724","article-title":"Prothrombin complex concentrate reduces blood loss and enhances thrombin generation in a pig model with blunt liver injury under severe hypothermia","volume":"106","author":"Honickel","year":"2011","journal-title":"Thromb Haemost"},{"issue":"3","key":"2020081220210660800_i1543-2165-139-12-1568-b28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/bja\/aen391","article-title":"Prothrombin complex concentrate vs fresh frozen plasma for reversal of dilutional coagulopathy in a porcine trauma model","volume":"102","author":"Dickneite","year":"2009","journal-title":"Br J Anaesth"},{"issue":"5","key":"2020081220210660800_i1543-2165-139-12-1568-b29","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/TA.0b013e3181b06364","article-title":"Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model","volume":"68","author":"Dickneite","year":"2010","journal-title":"J Trauma"},{"issue":"7","key":"2020081220210660800_i1543-2165-139-12-1568-b30","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood-2011-03-343046","article-title":"Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury","volume":"118","author":"Grottke","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2020081220210660800_i1543-2165-139-12-1568-b31","first-page":"203","article-title":"Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy","volume":"5","author":"van Veen","year":"2007","journal-title":"Blood Transfus"},{"issue":"1","key":"2020081220210660800_i1543-2165-139-12-1568-b32","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2516.2008.01878.x","article-title":"Prophylaxis with prothrombin complex concentrate in four children with severe congenital factor X deficiency","volume":"15","author":"Bowles","year":"2009","journal-title":"Haemophilia"},{"issue":"2","key":"2020081220210660800_i1543-2165-139-12-1568-b33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00043426-199205000-00012","article-title":"Prevention of recurrent intracranial hemorrhage in a factor X-deficient infant","volume":"14","author":"Sandler","year":"1992","journal-title":"Am J Pediatr Hematol Oncol"},{"issue":"6","key":"2020081220210660800_i1543-2165-139-12-1568-b34","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1365-2516.2008.01856.x","article-title":"Diagnosis and treatment of inherited factor X deficiency","volume":"14","author":"Brown","year":"2008","journal-title":"Haemophilia"},{"issue":"4","key":"2020081220210660800_i1543-2165-139-12-1568-b35","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/1076029610365331","article-title":"Prothrombin complex concentrate such as therapy and prophylaxis in factor X-deficient patient (Friuli variant)","volume":"17","author":"Barillari","year":"2011","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"2020081220210660800_i1543-2165-139-12-1568-b36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1365-2516.2001.00485.x","article-title":"Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrate","volume":"7","author":"Kouides","year":"2001","journal-title":"Haemophilia"},{"key":"2020081220210660800_i1543-2165-139-12-1568-b37","first-page":"605","article-title":"Protein-z-deficiency as a rare case of perioperative bleeding [in German]","volume":"38","author":"Barth","year":"2003","journal-title":"Anasthesiol Intensivmed Notfallmed Schmerzther"},{"issue":"1","key":"2020081220210660800_i1543-2165-139-12-1568-b38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0049-3848(95)00089-A","article-title":"Protein Z deficiency: a new cause of bleeding tendency","volume":"79","author":"Kemkes-Matthes","year":"1995","journal-title":"Thromb Res"},{"issue":"5","key":"2020081220210660800_i1543-2165-139-12-1568-b39","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/bja\/aes501","article-title":"Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P\/N): a pharmacovigilance study","volume":"110","author":"Hanke","year":"2013","journal-title":"Br J Anaesth"},{"issue":"3","key":"2020081220210660800_i1543-2165-139-12-1568-b40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12028-009-9310-0","article-title":"Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature","volume":"12","author":"Bershad","year":"2010","journal-title":"Neurocrit Care"},{"issue":"3","key":"2020081220210660800_i1543-2165-139-12-1568-b41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00277-009-0830-7","article-title":"Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal","volume":"89","author":"Pabinger","year":"2010","journal-title":"Ann Hematol"},{"key":"2020081220210660800_i1543-2165-139-12-1568-b42","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1537-2995.2008.02080.x","article-title":"Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratiodue to warfarin overdose","volume":"49","author":"Holland","year":"2009","journal-title":"Transfusion"},{"key":"2020081220210660800_i1543-2165-139-12-1568-b43","unstructured":"Octaplex (500 IU coagulation factor IX per vial, powder and solvent for infusion human prothrombin complex): summary of product characteristics, UK specific\n          [electronic prescribing information]. Octapharma AG. http:\/\/www.octapharma.co.uk\/fileadmin\/user_upload\/Octapharma_UK_New\/OPX1304.pdf. AccessedJune242014."},{"issue":"8","key":"2020081220210660800_i1543-2165-139-12-1568-b44","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/j.1537-2995.2009.02198.x","article-title":"Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6\u00b0C storage","volume":"49","author":"Scott","year":"2009","journal-title":"Transfusion"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/12\/1568\/2271541\/arpa_2014-0366-rs.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/139\/12\/1568\/2271541\/arpa_2014-0366-rs.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:36:02Z","timestamp":1764790562000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/139\/12\/article-p1568.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,1]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2014-0366-rs","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"type":"electronic","value":"1543-2165"},{"type":"print","value":"0003-9985"}],"subject":[],"published":{"date-parts":[[2014,12,1]]}}}